Whalesbook
Strong Q4 Results: Profit and Revenue Surge
Cupid Ltd. delivered striking financial results for its fourth quarter. Net profit jumped nearly threefold year-on-year to ₹36.3 crore, up from ₹11.5 crore in the same period last year. Revenue more than doubled to ₹120 crore from ₹56.5 crore, showing strong business momentum. The company also improved efficiency, with EBITDA rising sharply to ₹37.6 crore from ₹13.5 crore. Its EBITDA margin expanded to 31.3% from 23.9%, showcasing effective cost management and efficient scaling.
Stock Falls Amid Valuation Concerns
Despite the headline financial numbers, Cupid's stock faced immediate pressure, falling 2.21% to ₹120.36 on Friday. This drop comes after extraordinary long-term gains, with the stock appreciating by over 542% in the last twelve months. The company's P/E ratio of around 195x is a significant premium compared to industry peers like Hindustan Unilever (50.28x) and Godrej Consumer Products (56.71x). Although Cupid is debt-free and boasts higher margins than rivals such as Mankind Pharma, its high valuation suggests lofty market expectations. Analysts have yet to form a clear consensus, and price targets are not readily available.
Investor Concerns Over Valuation
The P/E ratio of nearly 200x signals significant risk, suggesting the stock price already factors in substantial future growth that may be hard to achieve. The stock's impressive historical performance has outpaced earnings growth over the past three and five years, pointing to a possible disconnect between its valuation and market enthusiasm. Prior quarterly results, such as Q4 FY25, showed a decline in revenue and net profit year-on-year, showing performance can fluctuate and be impacted by previous weaker periods. Competition is fierce from larger, more diversified players like Mankind Pharma and TTK Healthcare, which have established consumer brands. Cupid focuses on a B2B and B2G manufacturing model. Additionally, Cupid does not pay dividends. An increase in debtor and working capital days over time could suggest potential cash flow management pressures.
Future Outlook
The Indian healthcare and personal care sectors are poised for growth, driven by digitalization, increasing consumer sophistication, and a focus on preventive wellness. Cupid is well-positioned to benefit from these trends, particularly in its export markets and government contracts. Analysts had expected revenue growth of about 17% and a 15% profit increase for Q4 FY26, with actual results exceeding these more measured expectations. The company's debt-free status and strong margins provide a solid foundation, but maintaining this valuation will demand exceptional execution and market expansion to meet investor hopes.